SCHEMBL24330447

SCHEMBL24330447

COC(=O)c1ccc(COc2cccc(C3CCN(C(=O)OC(C)(C)C)CC3)n2)cc1F

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 2/20 0.46
TRPV3 Q8NET8 2/20 0.46
GLP1R P43220 4/20 0.45
GPR119 Q8TDV5 4/20 0.42
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.40
CNR1 P21554 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
GPR35 Q9HC97 1/20 0.40
GPR55 Q9Y2T6 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29555212 0.92 PRMT5 (0.49) PRMT5TRPV3GLP1RGPR119MAPT
SCHEMBL24329756 0.92 PRMT5 (0.49) PRMT5TRPV3GLP1RGPR119MAPT
SCHEMBL29554959 0.92 PRMT5 (0.47) PRMT5TRPV3GLP1RGPR119MAPT
SCHEMBL24329241 0.92 PRMT5 (0.47) PRMT5TRPV3GLP1RGPR119MAPT
SCHEMBL24329305 0.90 PRMT5 (0.46) PRMT5TRPV3GPR119TP53MAPT
SCHEMBL29555145 0.89 GLP1R (0.49) GLP1R
SCHEMBL30568153 0.89 GPR119 (0.55) PRMT5TRPV3GLP1RGPR119
SCHEMBL25340508 0.89 GPR119 (0.55) PRMT5TRPV3GLP1RGPR119
SCHEMBL24329559 0.85 TRPV3 (0.44) TRPV3GLP1R
SCHEMBL24329294 0.85 TRPV3 (0.45) PRMT5TRPV3GLP1RGPR119MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263402-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) 2025-08-21 US disclosed
EP-4227299-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) 2023-08-16 EP disclosed
EP-4227299-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) 2023-08-16 EP disclosed
CN-116348464-A Benzimidazolone GLP-1 receptor agonists and uses thereof 杭州中美华东制药有限公司 2023-06-27 CN disclosed
WO-2022078152-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF 杭州中美华东制药有限公司 2022-04-21 WO disclosed
WO-2022078152-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF 杭州中美华东制药有限公司 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250263402-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF GLP1R, GIPR, GCGR PRMT5 3198/4885TRPV3 316/4885GLP1R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.